Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 114 entries
Sorted by: Best Match Show Resources per page
Relief of vasospasm with fasudil after off-pump coronary artery bypass grafting: a case study.

Surgical case reports

Fujita A, Kurazumi H, Suzuki R, Takahashi M, Mikamo A, Hamano K.
PMID: 30051150
Surg Case Rep. 2018 Jul 27;4(1):82. doi: 10.1186/s40792-018-0481-9.

BACKGROUND: Coronary vasospasm after coronary artery bypass grafting (CABG) is a rare but potentially lethal complication. It is often refractory to several vasodilators. We report a case of refractory coronary vasospasm relieved by fasudil injection.CASE PRESENTATION: A 74-year-old woman...

Cite
Fujita A, Kurazumi H, Suzuki R, et al. Relief of vasospasm with fasudil after off-pump coronary artery bypass grafting: a case study. Surg Case Rep. 2018;4(1):82doi: 10.1186/s40792-018-0481-9.
Fujita, A., Kurazumi, H., Suzuki, R., Takahashi, M., Mikamo, A., & Hamano, K. (2018). Relief of vasospasm with fasudil after off-pump coronary artery bypass grafting: a case study. Surgical case reports, 4(1), 82. https://doi.org/10.1186/s40792-018-0481-9
Fujita, Akira, et al. "Relief of vasospasm with fasudil after off-pump coronary artery bypass grafting: a case study." Surgical case reports vol. 4,1 (2018): 82. doi: https://doi.org/10.1186/s40792-018-0481-9
Fujita A, Kurazumi H, Suzuki R, Takahashi M, Mikamo A, Hamano K. Relief of vasospasm with fasudil after off-pump coronary artery bypass grafting: a case study. Surg Case Rep. 2018 Jul 27;4(1):82. doi: 10.1186/s40792-018-0481-9. PMID: 30051150; PMCID: PMC6062643.
Copy Download .nbib Format: NLM
Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats.

Journal of geriatric cardiology : JGC

He WK, Su Q, Liang JB, Wang XT, Sun YH, Li L.
PMID: 30344543
J Geriatr Cardiol. 2018 Sep 28;15(9):591-597. doi: 10.11909/j.issn.1671-5411.2018.09.002.

BACKGROUND: Nicorandil (NIC) is a vasodilatory drug used to treat angina. However, its efficacy of cardioprotection in coronary microembolization (CME) is largely unknown. This study was undertaken to determine whether nicorandil pretreatment could attenuate myocardial apoptosis and improve cardiac...

Cite
He WK, Su Q, Liang JB, et al. Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats. J Geriatr Cardiol. 2018;15(9):591-597doi: 10.11909/j.issn.1671-5411.2018.09.002.
He, W. K., Su, Q., Liang, J. B., Wang, X. T., Sun, Y. H., & Li, L. (2018). Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats. Journal of geriatric cardiology : JGC, 15(9), 591-597. https://doi.org/10.11909/j.issn.1671-5411.2018.09.002
He, Wen-Kai, et al. "Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats." Journal of geriatric cardiology : JGC vol. 15,9 (2018): 591-597. doi: https://doi.org/10.11909/j.issn.1671-5411.2018.09.002
He WK, Su Q, Liang JB, Wang XT, Sun YH, Li L. Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats. J Geriatr Cardiol. 2018 Sep 28;15(9):591-597. doi: 10.11909/j.issn.1671-5411.2018.09.002. PMID: 30344543; PMCID: PMC6188981.
Copy Download .nbib Format: NLM
Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial.

American heart journal

Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J.
PMID: 34785173
Am Heart J. 2021 Nov 13; doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 13.

BACKGROUND: The efficacy and safety of intravenous infusion of nicorandil during primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) remain uncertain.OBJECTIVES: The primary objective of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial...

Cite
Huang D, Wu H, Zhou J, et al. Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial. Am Heart J. 2021;doi: 10.1016/j.ahj.2021.11.005.
Huang, D., Wu, H., Zhou, J., Zhong, X., Gao, W., Ma, Y., Qian, J., & Ge, J. (2021). Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial. American heart journal, . https://doi.org/10.1016/j.ahj.2021.11.005
Huang, Dong, et al. "Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial." American heart journal vol. (2021). doi: https://doi.org/10.1016/j.ahj.2021.11.005
Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J. Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial. Am Heart J. 2021 Nov 13; doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 13. PMID: 34785173.
Copy Download .nbib Format: NLM
Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention.

Journal of thoracic disease

Pi SF, Liu YW, Li T, Wang Y, Zhou Q, Liu BJ, Peng WJ, Li X, Wang YY, Huang L.
PMID: 31019762
J Thorac Dis. 2019 Mar;11(3):744-752. doi: 10.21037/jtd.2019.02.23.

BACKGROUND: This study aims to observe the effects of the intracoronary and peripheral venous administration of nicorandil for the postoperative myocardial microcirculation and short-term prognosis of ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI) treatment.METHODS:...

Cite
Pi SF, Liu YW, Li T, et al. Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention. J Thorac Dis. 2019;11(3):744-752doi: 10.21037/jtd.2019.02.23.
Pi, S. F., Liu, Y. W., Li, T., Wang, Y., Zhou, Q., Liu, B. J., Peng, W. J., Li, X., Wang, Y. Y., & Huang, L. (2019). Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention. Journal of thoracic disease, 11(3), 744-752. https://doi.org/10.21037/jtd.2019.02.23
Pi, Shu-Fang, et al. "Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention." Journal of thoracic disease vol. 11,3 (2019): 744-752. doi: https://doi.org/10.21037/jtd.2019.02.23
Pi SF, Liu YW, Li T, Wang Y, Zhou Q, Liu BJ, Peng WJ, Li X, Wang YY, Huang L. Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention. J Thorac Dis. 2019 Mar;11(3):744-752. doi: 10.21037/jtd.2019.02.23. PMID: 31019762; PMCID: PMC6462716.
Copy Download .nbib Format: NLM
Preconditioning Strategies to Enhance Neural Stem Cell-Based Therapy for Ischemic Stroke.

Brain sciences

Othman FA, Tan SC.
PMID: 33238363
Brain Sci. 2020 Nov 23;10(11). doi: 10.3390/brainsci10110893.

Transplantation of neural stem cells (NSCs) has been proposed as an alternative novel therapy to replace damaged neural circuitry after ischemic stroke onset. Nonetheless, albeit the potential of these cells for stroke therapy, many critical challenges are yet to...

Cite
Othman FA, Tan SC. Preconditioning Strategies to Enhance Neural Stem Cell-Based Therapy for Ischemic Stroke. Brain Sci. 2020;10(11)doi: 10.3390/brainsci10110893.
Othman, F. A., & Tan, S. C. (2020). Preconditioning Strategies to Enhance Neural Stem Cell-Based Therapy for Ischemic Stroke. Brain sciences, 10(11), . https://doi.org/10.3390/brainsci10110893
Othman, Farah Amna, and Tan, Suat Cheng. "Preconditioning Strategies to Enhance Neural Stem Cell-Based Therapy for Ischemic Stroke." Brain sciences vol. 10,11 (2020). doi: https://doi.org/10.3390/brainsci10110893
Othman FA, Tan SC. Preconditioning Strategies to Enhance Neural Stem Cell-Based Therapy for Ischemic Stroke. Brain Sci. 2020 Nov 23;10(11). doi: 10.3390/brainsci10110893. PMID: 33238363; PMCID: PMC7700351.
Copy Download .nbib Format: NLM
Additional decrease in fractional flow reserve in the left anterior descending artery after hand-grip exercise during pharmacological coronary hyperemia.

Heart and vessels

Shibutani H, Fujii K, Hashimoto K, Tsujimoto S, Matsumura K, Otagaki M, Morishita S, Shiojima I.
PMID: 33830316
Heart Vessels. 2021 Nov;36(11):1611-1616. doi: 10.1007/s00380-021-01846-7. Epub 2021 Apr 08.

Maximal hyperemia at the time of fractional flow reserve (FFR) measurement is generally induced by vasodilators, even when hyperemia at the onset of angina symptoms is caused by exercise stress. This study was designed to evaluate whether pharmacological hyperemia...

Cite
Shibutani H, Fujii K, Hashimoto K, et al. Additional decrease in fractional flow reserve in the left anterior descending artery after hand-grip exercise during pharmacological coronary hyperemia. Heart Vessels. 2021;36(11):1611-1616doi: 10.1007/s00380-021-01846-7.
Shibutani, H., Fujii, K., Hashimoto, K., Tsujimoto, S., Matsumura, K., Otagaki, M., Morishita, S., & Shiojima, I. (2021). Additional decrease in fractional flow reserve in the left anterior descending artery after hand-grip exercise during pharmacological coronary hyperemia. Heart and vessels, 36(11), 1611-1616. https://doi.org/10.1007/s00380-021-01846-7
Shibutani, Hiroki, et al. "Additional decrease in fractional flow reserve in the left anterior descending artery after hand-grip exercise during pharmacological coronary hyperemia." Heart and vessels vol. 36,11 (2021): 1611-1616. doi: https://doi.org/10.1007/s00380-021-01846-7
Shibutani H, Fujii K, Hashimoto K, Tsujimoto S, Matsumura K, Otagaki M, Morishita S, Shiojima I. Additional decrease in fractional flow reserve in the left anterior descending artery after hand-grip exercise during pharmacological coronary hyperemia. Heart Vessels. 2021 Nov;36(11):1611-1616. doi: 10.1007/s00380-021-01846-7. Epub 2021 Apr 08. PMID: 33830316.
Copy Download .nbib Format: NLM
Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Experimental and therapeutic medicine

Xu X, Liu X, Yu L, Ma J, Yu S, Ni M.
PMID: 31853283
Exp Ther Med. 2020 Jan;19(1):137-146. doi: 10.3892/etm.2019.8219. Epub 2019 Nov 19.

The present study aimed to clarify the effect of bolus intracoronary nicorandil on inflammatory, oxidative and adherent indicators in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). This randomized controlled trial (RCT) was performed to detect...

Cite
Xu X, Liu X, Yu L, et al. Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med. 2019;19(1):137-146doi: 10.3892/etm.2019.8219.
Xu, X., Liu, X., Yu, L., Ma, J., Yu, S., & Ni, M. (2020). Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Experimental and therapeutic medicine, 19(1), 137-146. https://doi.org/10.3892/etm.2019.8219
Xu, Xingli, et al. "Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention." Experimental and therapeutic medicine vol. 19,1 (2020): 137-146. doi: https://doi.org/10.3892/etm.2019.8219
Xu X, Liu X, Yu L, Ma J, Yu S, Ni M. Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Exp Ther Med. 2020 Jan;19(1):137-146. doi: 10.3892/etm.2019.8219. Epub 2019 Nov 19. PMID: 31853283; PMCID: PMC6909796.
Copy Download .nbib Format: NLM
Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss.

Frontiers in pharmacology

Xu S, Cao X, Yu Z, He W, Pang Y, Lin W, Chen Z, Guo W, Lu X, Lin C.
PMID: 34566650
Front Pharmacol. 2021 Sep 08;12:726361. doi: 10.3389/fphar.2021.726361. eCollection 2021.

Osteolytic bone disorders are characterized by an overall reduction in bone mineral density which enhances bone ductility and vulnerability to fractures. This disorder is primarily associated with superabundant osteoclast formation and bone resorption activity. Nicorandil (NIC) is a vasodilatory...

Cite
Xu S, Cao X, Yu Z, et al. Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss. Front Pharmacol. 2021;12:726361doi: 10.3389/fphar.2021.726361.
Xu, S., Cao, X., Yu, Z., He, W., Pang, Y., Lin, W., Chen, Z., Guo, W., Lu, X., & Lin, C. (2021). Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss. Frontiers in pharmacology, 12726361. https://doi.org/10.3389/fphar.2021.726361
Xu, Shenggui, et al. "Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss." Frontiers in pharmacology vol. 12 (2021): 726361. doi: https://doi.org/10.3389/fphar.2021.726361
Xu S, Cao X, Yu Z, He W, Pang Y, Lin W, Chen Z, Guo W, Lu X, Lin C. Nicorandil Inhibits Osteoclast Formation Base on NF-κB and p-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss. Front Pharmacol. 2021 Sep 08;12:726361. doi: 10.3389/fphar.2021.726361. eCollection 2021. PMID: 34566650; PMCID: PMC8455841.
Copy Download .nbib Format: NLM
Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions.

American journal of translational research

Zhang J, Xin Z.
PMID: 34377269
Am J Transl Res. 2021 Jul 15;13(7):7906-7913. eCollection 2021.

OBJECTIVE: This research was designed to investigate the efficacy of metoprolol combined with nicorandil on unstable angina pectoris (UAP).METHODS: Totally 174 UAP patients treated in the Laixi City People's Hospital from May 2017 to December 2019 were taken as...

Cite
Zhang J, Xin Z. Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions. Am J Transl Res. 2021;13(7):7906-7913
Zhang, J., & Xin, Z. (2021). Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions. American journal of translational research, 13(7), 7906-7913.
Zhang, Junhua, and Xin, Zhi. "Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions." American journal of translational research vol. 13,7 (2021): 7906-7913.
Zhang J, Xin Z. Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions. Am J Transl Res. 2021 Jul 15;13(7):7906-7913. eCollection 2021. PMID: 34377269; PMCID: PMC8340211.
Copy Download .nbib Format: NLM
Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial.

American heart journal

Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J.
PMID: 34785173
Am Heart J. 2022 Feb;244:86-93. doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 14.

BACKGROUND: The efficacy and safety of intravenous infusion of nicorandil during primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) remain uncertain.OBJECTIVES: The primary objective of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial...

Cite
Huang D, Wu H, Zhou J, et al. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. Am Heart J. 2021;244:86-93doi: 10.1016/j.ahj.2021.11.005.
Huang, D., Wu, H., Zhou, J., Zhong, X., Gao, W., Ma, Y., Qian, J., & Ge, J. (2022). Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. American heart journal, 24486-93. https://doi.org/10.1016/j.ahj.2021.11.005
Huang, Dong, et al. "Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial." American heart journal vol. 244 (2022): 86-93. doi: https://doi.org/10.1016/j.ahj.2021.11.005
Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. Am Heart J. 2022 Feb;244:86-93. doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 14. PMID: 34785173.
Copy Download .nbib Format: NLM
Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial.

American heart journal

Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J.
PMID: 34785173
Am Heart J. 2021 Nov 14;244:86-93. doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 14.

BACKGROUND: The efficacy and safety of intravenous infusion of nicorandil during primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI) remain uncertain.OBJECTIVES: The primary objective of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial...

Cite
Huang D, Wu H, Zhou J, et al. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. Am Heart J. 2021;244:86-93doi: 10.1016/j.ahj.2021.11.005.
Huang, D., Wu, H., Zhou, J., Zhong, X., Gao, W., Ma, Y., Qian, J., & Ge, J. (2021). Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. American heart journal, 24486-93. https://doi.org/10.1016/j.ahj.2021.11.005
Huang, Dong, et al. "Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial." American heart journal vol. 244 (2021): 86-93. doi: https://doi.org/10.1016/j.ahj.2021.11.005
Huang D, Wu H, Zhou J, Zhong X, Gao W, Ma Y, Qian J, Ge J. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction: Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil (CLEAN) trial. Am Heart J. 2021 Nov 14;244:86-93. doi: 10.1016/j.ahj.2021.11.005. Epub 2021 Nov 14. PMID: 34785173.
Copy Download .nbib Format: NLM
Peroxidatic activity in heart effluent: a biochemical parameter for the assessment of experimental ischemia-reperfusion injury.

Journal of cellular and molecular medicine

Leabu MV, Bucur EA.
PMID: 12167286
J Cell Mol Med. 2000 Jul-Sep;4(3):176-182. doi: 10.1111/j.1582-4934.2000.tb00115.x.

Peroxidatic activity in heart effluent was defined as a new biochemical parameter for the experimental study of myocardial ischemia. The peroxidatic reaction was determined by dot blot analysis with 3,3'-diaminobenzidine as hydrogen donor. After ischemia, the level of peroxidatic...

Cite
Leabu MV, Bucur EA. Peroxidatic activity in heart effluent: a biochemical parameter for the assessment of experimental ischemia-reperfusion injury. J Cell Mol Med. 2000;4(3):176-182doi: 10.1111/j.1582-4934.2000.tb00115.x.
Leabu, M. V., & Bucur, E. A. (2000). Peroxidatic activity in heart effluent: a biochemical parameter for the assessment of experimental ischemia-reperfusion injury. Journal of cellular and molecular medicine, 4(3), 176-182. https://doi.org/10.1111/j.1582-4934.2000.tb00115.x
Leabu, M. V., and Bucur, Elisa A.. "Peroxidatic activity in heart effluent: a biochemical parameter for the assessment of experimental ischemia-reperfusion injury." Journal of cellular and molecular medicine vol. 4,3 (2000): 176-182. doi: https://doi.org/10.1111/j.1582-4934.2000.tb00115.x
Leabu MV, Bucur EA. Peroxidatic activity in heart effluent: a biochemical parameter for the assessment of experimental ischemia-reperfusion injury. J Cell Mol Med. 2000 Jul-Sep;4(3):176-182. doi: 10.1111/j.1582-4934.2000.tb00115.x. PMID: 12167286; PMCID: PMC6741292.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 114 entries